Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, February 16, 2026

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

 What is your competent? doctor and hospital doing to prevent reperfusion injury?

  • reperfusion injury (39 posts to January 2013) So incompetent for well over a decade!

    • Oh, NOTHING AT ALL?

    Being incompetent like usual?

    Do you prefer your doctor, hospital and board of director's incompetence NOT KNOWING? OR NOT DOING? Your choice; let them be incompetent or demand action!


    Optimizing Reperfusion to Improve Outcomes and Neurologic Function

    linicalTrials.gov IDNCT06990867
    SponsorCorxel Pharmaceuticals
    Information Provided bySenior Director, Clinical Operations
    Study Start (Actual)2025-05-15
    Primary Completion (Estimated) 2029-10-31
    Study Completion (Estimated)2029-12-31
    Enrollment (Estimated)740
    Study TypeInterventional
    Last Update Posted2026-02-11

    Study Overview

    Brief Summary

    The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1. JX10 improves functional outcomes as measured by the modified Rankin Scale score when compared with placebo following AIS. 2. Risk of symptomatic intracranial hemorrhage of JX10 in participants with AIS. During Part 1, participants will be randomized to JX 10 (1mg/kg, 3 mg/kg) or placebo. During Part 2, participants will receive JX10 (optimal dose chosen from Part 1) or placebo.

    To learn more, visitClinicalTrials.gov

    Posted by at
    Labels: , , , , , ,

    No comments:

    Post a Comment

    Subscribe to: Post Comments (Atom)